Every 8-K that Tg Therapeutics Inc (TGTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TGTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TGTX filings page.
TG Therapeutics reported higher Q2 2026 revenue led by BRIUMVI. Total revenue reached $240.3 million, up from $141.1 million a year earlier. Product revenue was $235.8 million, driven by BRIUMVI U.S. net product revenue of $227.7 million, approximately 64% higher than the prior-year quarter, plus $8.1 million of BRIUMVI sales to ex-U.S. partner Neuraxpharm and $4.5 million of license, milestone, royalty and other revenue.
Operating income was $21.7 million, but net income declined to $7.8 million from $28.2 million as cost of revenue rose to $41.2 million, R&D expense increased to $95.3 million (including $54.6 million for subcutaneous BRIUMVI manufacturing and secondary manufacturer costs), and SG&A expense grew to $82.1 million, alongside higher interest expense of $16.6 million.
Cash, cash equivalents and investment securities were $612.3 million at June 30, 2026, and the company expects this plus projected BRIUMVI revenue to fund its current operating plan. Full‑year 2026 guidance was raised to approximately $950 million in total global revenue and $890–$905 million in BRIUMVI U.S. net product revenue, with targeted operating expenses of $350–$400 million excluding non‑cash compensation and about $100 million for subcutaneous BRIUMVI manufacturing and secondary manufacturer start‑up costs. Management also highlighted positive Phase 3 ENHANCE results and progress in subcutaneous BRIUMVI, myasthenia gravis, schizophrenia and the azer‑cel platform.
TG Therapeutics, Inc. reported results from its 2026 Annual Meeting, where stockholders representing 113,003,414 shares, or 73.81% of the 153,093,879 outstanding shares, were present, constituting a quorum. Six directors were elected, KPMG LLP was ratified as independent auditor, but the advisory vote on executive compensation was not approved, with 31,905,837 votes for and 48,858,169 against.
TG Therapeutics reported positive Phase 1 results for a high‑concentration, low‑volume subcutaneous formulation of BRIUMVI (ublituximab-xiiy) in adults with relapsing multiple sclerosis. The subcutaneous version was well tolerated and showed sustained drug exposure, supporting a quarterly dosing regimen.
These data underpin an ongoing, fully enrolled Phase 3 trial comparing quarterly and every‑other‑month subcutaneous dosing to the approved intravenous regimen, with topline results expected in late 2026 or early 2027. Management noted that, if ultimately approved, a self‑administered at‑home, quarterly anti‑CD20 therapy could significantly reduce injections versus current options and expand the addressable BRIUMVI market.
TG Therapeutics reported positive topline results from its Phase 3 ENHANCE trial of BRIUMVI in adults with relapsing forms of multiple sclerosis. The study met its primary endpoint, showing bioequivalent drug exposure between the currently approved two-step initiation regimen and a single 600 mg infusion on Day 1.
This consolidated regimen would eliminate the Day 15 infusion while keeping the same total 600 mg dose through Day 15. Safety and tolerability of the single-infusion start were consistent with the established BRIUMVI safety profile. The company is targeting submission of a supplemental biologics license application in the second half of 2026.
TG Therapeutics reported sharply improved first quarter 2026 results, driven by strong uptake of BRIUMVI for multiple sclerosis. Total revenue reached $204.9 million, up from $120.9 million a year earlier, producing operating income of $34.8 million and net income of $19.8 million.
Product revenue, mainly from BRIUMVI, was $201.3 million, while cash, cash equivalents and investment securities grew to $572.8 million as of March 31, 2026. Despite higher research, selling, general and administrative expenses, profitability and cash balances increased.
Reflecting this momentum, the company raised its full-year 2026 total global revenue target to about $925 million and increased its BRIUMVI U.S. net product revenue guidance to $885–900 million, signaling confidence in ongoing demand and commercial execution.
TG Therapeutics entered into a major debt amendment that creates a new $750 million 2026 term loan, which was fully drawn on March 18, 2026. Part of the proceeds repaid the company’s existing initial term loans, effectively refinancing its capital structure while keeping Blue Owl Capital Corporation as administrative agent.
The loan matures on March 18, 2031 and carries a variable interest rate based on either a base rate or Term SOFR, plus a margin tied to the company’s total net leverage ratio. Margins start at 4.75% for SOFR and 3.75% for base rate borrowings and can step down by 0.25% if leverage improves. Beginning in the quarter ending March 31, 2030, the agreement requires quarterly principal payments of $37.5 million, with the remaining balance due at maturity, though these installments may be deferred to maturity if a leverage threshold is met.
The 2026 term loan is secured by liens on substantially all assets of TG Therapeutics and certain subsidiaries and includes customary covenants and default provisions for this type of financing, giving lenders rights to accelerate repayment if an event of default occurs.
TG Therapeutics reported strong growth for the fourth quarter and full year 2025, led by BRIUMVI. Q4 2025 total revenue was $192.6 million, including BRIUMVI U.S. net revenue of $182.7 million. Full-year 2025 total revenue reached $616.3 million, with BRIUMVI U.S. net revenue of $594.1 million.
Total 2025 revenue rose sharply from $329.0 million in 2024, and net income increased to $447.2 million from $23.4 million. The company issued 2026 guidance targeting approximately $875–900 million in total global revenue, Q1 2026 BRIUMVI U.S. net product revenue of $185–190 million, and about $350 million in operating expenses plus $100 million in subcutaneous BRIUMVI manufacturing and start-up costs.
TG Therapeutics, Inc. filed a current report to share that it has released a press release providing preliminary fourth quarter and full year 2025 net product revenue, along with 2026 revenue guidance and anticipated development milestones.
The company furnished this information under a Regulation FD disclosure, attaching the full press release as Exhibit 99.1. The exhibit contains the detailed financial figures and milestone timelines, while the report itself mainly documents that this information has been made publicly available.
TG Therapeutics, Inc. filed a current report to note that it has released its financial results. On November 3, 2025, the company issued a press release covering its results of operations for the three and nine months ended September 30, 2025, and furnished that release as Exhibit 99.1. The information about these quarterly and year-to-date results is being furnished, not filed, which means it is not automatically subject to certain liability provisions or incorporated into other SEC filings unless specifically referenced.